IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:00 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:00 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q4 owing to continued rise in Catalyst and premium hematology placements.
Why You Should Hold Molina Healthcare (MOH) in Your Portfolio
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.
Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Why Idexx (IDXX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement
by Zacks Equity Research
IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.
5 Stocks Powering Nasdaq ETF to Start 2023
by Sweta Killa
The rally has been broad-based. And the high beta and high growth sector took charge, with the tech-heavy Nasdaq Composite Index rising 5.1% in the initial two weeks of 2023.
Here's Why You Should Invest in IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) owing to strong international growth.
IDEXX (IDXX) CAG Sales Growth Strong, Costs Continue to Rise
by Zacks Equity Research
IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.
Avanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Q3 Earnings Beat Estimates, 2022 EPS View Down
by Zacks Equity Research
IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 5.39% and 1.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pet Industry Seems Recession-Proof: ETF & Stocks in Focus
by Sanghamitra Saha
American Pet Products Association, 70% of U.S. households own a pet, as quoted on Yahoo Finance. And Americans are splurging on their pets despite high inflation.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.
Why Is Idexx (IDXX) Down 14.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OCPNY vs. IDXX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints
by Zacks Equity Research
The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.
IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.
Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Quotient (QTNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OCPNY or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
3 MedTech Stocks That are Likely to Beat This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.